Topoisomerase IIα gene (TOP2A) amplification and deletion in cancer - More common than anticipated

Cytopathology

Volumn 14, Issue 6, 2003, Pages 309-313

  Jarvinen T A H ^a,b   Liu, E T ^c  

^a BURNHAM INSTITUTE   (United States)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c GENOME INSTITUTE OF SINGAPORE   (Singapore)

Author keywords

Breast cancer; Deletion; Gene amplification; HER 2 ErbB2 c erbB2 HER 2 neu; Prevalence; Topoisomerase II (TOP2A)

Indexed keywords

GYRASE INHIBITOR; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; TUMOR ANTIGEN;

AMPLICON; BREAST CANCER; CANCER; CANCER THERAPY; CHEMOSENSITIVITY; CHROMOSOME 17Q; DRUG RESISTANCE; DRUG SENSITIVITY; GENE; GENE ACTIVATION; GENE AMPLIFICATION; GENE DELETION; GENE LOCATION; GENE LOCUS; GENE MUTATION; GENETIC SCREENING; MOLECULAR GENETICS; ONCOGENE; ONCOGENE NEU; PREVALENCE; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TOPOISOMERASE IIALPHA GENE; BREAST TUMOR; GENETICS; HUMAN; NOTE; PATHOLOGY;

ANTIGENS, NEOPLASM; BREAST NEOPLASMS; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; GENE AMPLIFICATION; GENE DELETION; HUMANS;

EID: 0346244044     PISSN: 09565507     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0956-5507.2003.00105.x     Document Type: Review

References (24)

1. Järvinen TAH, Liu ET. HER-2/neu and topoisomerase IIα in breast cancer. Breast Cancer Res Treat 2003;78:299-311.
2. Ross JS, Fletcher JA. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol 1999;112(Suppl. 1):S53-67.
3. Rubin I, Yarden Y. The basic biology of HER2. Ann Oncol 2001;12(Suppl. 1):S3-8.
4. Järvinen TAH, Liu ET. HER-2/neu and topoisomerase IIα genes, targets for chemotherapy. Comb Chem High Through Scr 2003;6:455-70.
5. Kauraniemi P, Bärlund M, Monni O, Kallioniemi A. New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. Cancer Res 2001;61:8235-40.
6. Luoh SW. Amplification and expression of genes from the 17q11 approximately q12 amplicon in breast cancer cells. Cancer Genet Cytogenet 2002;136:43-7.
7. Hyman E, Kauraniemi P, Hautaniemi S et al. Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res 2002;62:6240-5.
8. Järvinen TAH, Tanner M, Bärlund M et al. Characterization of topoisomerase IIα amplification and deletion in breast cancer. Genes Chrom Cancer 1999;26:142-50.
9. Kauraniemi P, Kuukasjärvi T, Sauter G, Kallioniemi A. Amplification of a 280 kb core region at the ERBB2 locus leads to activation of two hypothetical proteins in breast cancer. Am J Pathol 2003;163:1979-84.
10. Champoux JJ. DNA topoisomerases: structure, function, and mechanism. Ann Rev Biochem 2001;70:369-413.
11. Järvinen TAH, Tanner M, Rantanen V et al. Amplification and deletion of topoisomerase IIα gene are common in ErbB-2 amplified breast cancer and alter the sensitivity to doxorubicin. Am J Pathol 2000;156:839-47.
12. Smith K, Houlbrook S, Greenall M, Carmichael J, Harris AL. Topoisomerase IIα co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. Oncogene 1993;8:933-8.
13. Withoff S, Keith WN, Knol AJ. Selection of a subpopulation with fewer DNA topoisomerase IIα gene copies in a doxorubicin-resistant cell line panel. Br J Cancer 1996;74:502-7.
14. Withoff S, de Vnes EG, Keith WN et al. Differential expression of DNA topoisomerase IIα and -β in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC. Br J Cancer 1996;74:1869-76.
15. Durbecq V, Di Leo A, Cardoso F et al. Comparison of topoisomerase- IIβ gene status between primary breast cancer and corresponding distant metastatic sites. Breast Cancer Res Treat 2003;77:199-204.
16. Bofin AM, Ytterhus B, Hagmar BM. TOP2A and HER-2 gene amplification in fine needle aspirates of breast carcinomas. Cytopathology 2003;14:314-321.
17. Varis A, Wolf M, Monni O et al. Targets of gene amplification and overexpression at 17q in gastric cancer. Cancer Res 2002;62:2625-9.
18. Wikman H, Kettunen E, Seppänen JK et al. Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA array. Oncogene 2002;21:5804-13.
19. Guérin E, Entz-Werlé N, Eyer D et al. Modification of topoisomerase genes copy number in newly diagnosed childhood acute lymphoblastic leukemia. Leukemia 2003;17:532-40.
20. Simon R, Atefy R, Wagner U et al. HER-2 and TOP2A coamplification in urinary bladder cancer. Int. J. Cancer 2003;107:764-772.
21. Tanner M, Järvinen TAH, Kauraniemi P, Holli K, Joensuu H. Topoisomerase IIα amplification and deletion predict response to chemotherapy in breast cancer. Proc Am Assoc Cancer Res 2000;41:803.
22. Coon JS, Marcus E, Gupta-Burt S et al. Amplification and overexpression of topoisomerase IIα predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 2002;8:1061-7.
23. Di Leo A, Gancberg D, Larsimont D et al. HER-2 amplification and topoisomerase IIα gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with CMF. Clin Cancer Res 2002;8:1107-16.
24. Park K, Kim J, Lim S, Han S. Topoisomerase II-α (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer 2003;39:631-4.